Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Dong Seop Choi  (Choi DS) 4 Articles
Epidemiology
Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea, 2003 to 2013
Kyeong Jin Kim, Tae Yeon Kwon, Sungwook Yu, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim, Yousung Park, Nam Hoon Kim
Diabetes Metab J. 2018;42(5):394-401.   Published online April 26, 2018
DOI: https://doi.org/10.4093/dmj.2017.0088
  • 4,850 View
  • 58 Download
  • 25 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   
Background

To estimate and compare the trends of all-cause and cause-specific mortality rates for subjects with and without diabetes in South Korea, from 2003 to 2013.

Methods

Using a population-based cohort (2003 to 2013), we evaluated annual mortality rates in adults (≥30 years) with and without diabetes. The number of subjects in this analysis ranged from 585,795 in 2003 to 670,020 in 2013.

Results

Age- and sex-adjusted all-cause mortality rates decreased consistently in both groups from 2003 to 2013 (from 14.4 to 9.3/1,000 persons in subjects with diabetes and from 7.9 to 4.4/1,000 persons in those without diabetes). The difference in mortality rates between groups also decreased (6.61 per 1,000 persons in 2003 to 4.98 per 1,000 persons in 2013). The slope associated with the mortality rate exhibited a steeper decrease in subjects with diabetes than those without diabetes (regression coefficients of time: −0.50 and −0.33, respectively; P=0.004). In subjects with diabetes, the mortality rate from cardiovascular disease decreased by 53.5% (from 2.73 to 1.27 per 1,000 persons, P for trend <0.001). Notably, the decrease in mortality from ischemic stroke (79.2%, from 1.20 to 0.25 per 1,000 persowns) was more profound than that from ischemic heart disease (28.3%, from 0.60 to 0.43 per 1,000 persons).

Conclusion

All-cause and cardiovascular mortality rates decreased substantially from 2003 to 2013, and the decline in ischemic stroke mortality mainly contributed to the decreased cardiovascular mortality in Korean people with diabetes.

Citations

Citations to this article as recorded by  
  • Green tea consumption and incidence of cardiovascular disease in type 2 diabetic patients with overweight/obesity: a community-based cohort study
    Bingyue Liu, Shujun Gu, Jin Zhang, Hui Zhou, Jian Su, Sudan Wang, Qian Sun, Zhengyuan Zhou, Jinyi Zhou, Chen Dong
    Archives of Public Health.2024;[Epub]     CrossRef
  • Trends in all-cause and cause-specific mortality in older adults with and without diabetes: A territory-wide analysis in one million older adults in Hong Kong
    Aimin Yang, Tingting Chen, Mai Shi, Eric Lau, Raymond SM Wong, Jones Chan, Juliana CN Chan, Elaine Chow
    Diabetes Research and Clinical Practice.2024; 210: 111618.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Letter: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86)
    Gwanpyo Koh
    Journal of Obesity & Metabolic Syndrome.2023; 32(2): 179.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
    Ye Seul Yang
    The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
  • The Characteristics and Risk of Mortality in the Elderly Korean Population
    Sunghwan Suh
    Endocrinology and Metabolism.2023; 38(5): 522.     CrossRef
  • Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
    Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
    Diabetes & Metabolism Journal.2022; 46(3): 464.     CrossRef
  • Health-related Quality of Life Instrument With 8 Items for Use in Patients With Type 2 Diabetes Mellitus: A Validation Study in Korea
    Juyoung Kim, Hyeon-Jeong Lee, Min-Woo Jo
    Journal of Preventive Medicine and Public Health.2022; 55(3): 234.     CrossRef
  • Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    Endocrinology and Metabolism.2022; 37(3): 466.     CrossRef
  • Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2022; 46(4): 543.     CrossRef
  • Diabetic Ketoacidosis and COVID-19: A Retrospective Observational Study
    Govind Nagdev, Gajanan Chavan, Charuta Gadkari, Gaurav Sahu
    Cureus.2022;[Epub]     CrossRef
  • Trends in the effects of pre‐transplant diabetes on mortality and cardiovascular events after kidney transplantation
    Ja Young Jeon, Soo Jung Kim, Kyoung Hwa Ha, Ji Hyun Park, Bumhee Park, Chang‐Kwon Oh, Seung Jin Han
    Journal of Diabetes Investigation.2021; 12(5): 811.     CrossRef
  • Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(2): 349.     CrossRef
  • Polysomnographic phenotyping of obstructive sleep apnea and its implications in mortality in Korea
    Jeong-Whun Kim, Tae-Bin Won, Chae-Seo Rhee, Young Mi Park, In-Young Yoon, Sung-Woo Cho
    Scientific Reports.2020;[Epub]     CrossRef
  • Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study
    Bo Kyung Koo, Woo-Young Chung, Min Kyong Moon
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Kidney Research and Clinical Practice.2020; 39(1): 32.     CrossRef
  • Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
    Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Mayo Clinic Proceedings.2020; 95(1): 101.     CrossRef
  • Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2020; 44(1): 3.     CrossRef
  • A systematic review of trends in all-cause mortality among people with diabetes
    Lei Chen, Rakibul M. Islam, Joanna Wang, Thomas R. Hird, Meda E. Pavkov, Edward W. Gregg, Agus Salim, Maryam Tabesh, Digsu N. Koye, Jessica L. Harding, Julian W. Sacre, Elizabeth L. M. Barr, Dianna J. Magliano, Jonathan E. Shaw
    Diabetologia.2020; 63(9): 1718.     CrossRef
  • Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature
    Pavan Kumar Reddy, Mohammad Shafi Kuchay, Yatin Mehta, Sunil Kumar Mishra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1459.     CrossRef
  • Prognostic value of long-term gamma-glutamyl transferase variability in individuals with diabetes: a nationwide population-based study
    Da Young Lee, Kyungdo Han, Ji Hee Yu, Sanghyun Park, Ji A Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Seon Mee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Nan Hee Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study
    Jeong Mi Kim, Sang Soo Kim, In Joo Kim, Jong Ho Kim, Bo Hyun Kim, Mi Kyung Kim, Soon Hee Lee, Chang Won Lee, Min Chul Kim, Jun Hyeob Ahn, Jinmi Kim
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study
    Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMC Medicine.2020;[Epub]     CrossRef
  • Increased Age of Death and Change in Causes of Death Among Persons With Diabetes Mellitus From the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
    Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(6): 909.     CrossRef
  • Diabetes Mellitus, Still Major Threat to Mortality from Various Causes
    Nam Hoon Kim
    Diabetes & Metabolism Journal.2019; 43(3): 273.     CrossRef
  • Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
    Sunghwan Suh, Kwang-Won Kim
    Diabetes & Metabolism Journal.2019; 43(6): 733.     CrossRef
  • Trends of Diabetes Epidemic in Korea
    Ji Cheol Bae
    Diabetes & Metabolism Journal.2018; 42(5): 377.     CrossRef
Clinical Diabetes & Therapeutics
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Soo Lim, Kyoung Min Kim, Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yongsoo Park, Sang Jin Kim, Hak Chul Jang, Dong Seop Choi
Diabetes Metab J. 2017;41(5):377-385.   Published online October 24, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.5.377
  • 4,244 View
  • 42 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this multicenter, randomized, double-blind study was to examine the effect of lobeglitazone, a novel thiazolidinedione, on the changes in bone mineral density (BMD) in patients with type 2 diabetes mellitus.

Methods

A 24-week, double-blinded phase was followed by a 28-week, open-label phase, in which the placebo group also started to receive lobeglitazone. A total of 170 patients aged 34 to 76 years were randomly assigned in a 2:1 ratio to receive lobeglitazone 0.5 mg or a matching placebo orally, once daily. BMD was assessed using dual-energy X-ray absorptiometry at week 24 and at the end of the study (week 52).

Results

During the double-blinded phase, the femur neck BMD showed decreasing patterns in both groups, without statistical significance (−0.85%±0.36% and −0.78%±0.46% in the lobeglitazone and placebo groups, respectively). The treatment difference between the groups was 0.07%, which was also not statistically significant. Further, minimal, nonsignificant decreases were observed in both groups in the total hip BMD compared to values at baseline, and these differences also did not significantly differ between the groups. During the open-label phase, the BMD was further decreased, but not significantly, by −0.32% at the femur neck and by −0.60% at the total hip in the lobeglitazone group, and these changes did not significantly differ compared with the original placebo group switched to lobeglitazone.

Conclusion

Our results indicate that treatment with lobeglitazone 0.5 mg over 52 weeks showed no detrimental effect on the BMD compared to the placebo.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
    Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
  • The benefits of adipocyte metabolism in bone health and regeneration
    Lisa-Marie Burkhardt, Christian H. Bucher, Julia Löffler, Charlotte Rinne, Georg N. Duda, Sven Geissler, Tim J. Schulz, Katharina Schmidt-Bleek
    Frontiers in Cell and Developmental Biology.2023;[Epub]     CrossRef
  • Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
  • Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
    Jun Hwa Hong, Jun Sung Moon, Kayeon Seong, Soo Lim
    Diabetes Research and Clinical Practice.2023; 203: 110872.     CrossRef
  • Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study
    Nitish Khandelwal, Surbhi Rajauria, Siddhesh Pandurang Kanjalkar, Omkar Shivaji Chavanke, Sanjay Rai
    Cureus.2023;[Epub]     CrossRef
  • Lobeglitazone and Its Therapeutic Benefits: A Review
    Balamurugan M, Sarumathy S, Robinson R
    Cureus.2023;[Epub]     CrossRef
  • A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
    Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
  • A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
    Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
    Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
    Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee, Bong-Soo Cha
    Diabetes & Metabolism Journal.2021; 45(3): 326.     CrossRef
  • Effect of lobeglitazone on motor function in rat model of Parkinson’s disease with diabetes co-morbidity
    Kambiz Hassanzadeh, Arman Rahimmi, Mohammad Raman Moloudi, Rita Maccarone, Massimo Corbo, Esmael Izadpanah, Marco Feligioni
    Brain Research Bulletin.2021; 173: 184.     CrossRef
  • Recent Perspective on Thiazolidinedione
    Won Jun Kim
    The Journal of Korean Diabetes.2021; 22(2): 97.     CrossRef
  • Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models
    Sabrina Ehnert, Helen Rinderknecht, Romina H. Aspera-Werz, Victor Häussling, Andreas K. Nussler
    Archives of Toxicology.2020; 94(12): 3937.     CrossRef
  • Update on: effects of anti-diabetic drugs on bone metabolism
    Guillaume Mabilleau, Béatrice Bouvard
    Expert Review of Endocrinology & Metabolism.2020; 15(6): 415.     CrossRef
  • The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta‐analysis of observational studies
    Khemayanto Hidayat, Xuan Du, Meng‐Jiao Wu, Bi‐Min Shi
    Obesity Reviews.2019; 20(10): 1494.     CrossRef
  • Diabetes pharmacotherapy and effects on the musculoskeletal system
    Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu, Kathryn M. Thrailkill
    Diabetes/Metabolism Research and Reviews.2019;[Epub]     CrossRef
  • Morin Exerts Anti‐Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor‐γ
    Mengfan Yue, Ni Zeng, Yufeng Xia, Zhifeng Wei, Yue Dai
    Molecular Nutrition & Food Research.2018;[Epub]     CrossRef
  • The effects of diabetes therapy on bone: A clinical perspective
    Karim G. Kheniser, Carmen M. Polanco Santos, Sangeeta R. Kashyap
    Journal of Diabetes and its Complications.2018; 32(7): 713.     CrossRef
  • Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
    Da Young Lee, Ji A Seo
    Diabetes & Metabolism Journal.2017; 41(5): 374.     CrossRef
Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease
Hae Yoon Choi, Soon Young Hwang, Chang Hee Lee, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi
Diabetes Metab J. 2013;37(1):63-71.   Published online February 15, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.1.63
  • 4,935 View
  • 37 Download
  • 85 Crossref
AbstractAbstract PDFPubReader   
Background

Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD).

Methods

We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV).

Results

Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007).

Conclusion

Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Citations

Citations to this article as recorded by  
  • Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
    Guillaume Henin, Audrey Loumaye, Isabelle A. Leclercq, Nicolas Lanthier
    JHEP Reports.2024; 6(2): 100963.     CrossRef
  • Association between serum trace element, mineral, and amino acid levels with non-alcoholic fatty liver disease (NAFLD) in adult women
    Alexey A. Tinkov, Tatiana V. Korobeinikova, Galina D. Morozova, Michael Aschner, Daria V. Mak, Abel Santamaria, Joao B.T. Rocha, Tatiana I. Sotnikova, Serafima Ia. Tazina, Anatoly V. Skalny
    Journal of Trace Elements in Medicine and Biology.2024; 83: 127397.     CrossRef
  • Adipose-derived extracellular vesicles – a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
    Dušan Mladenović, Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Lena Radić, Jelica Bjekić Macut, Djuro Macut
    Endocrine.2024;[Epub]     CrossRef
  • Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
    Qiuyu Xu, Jie Zhang, Yan Lu, Ling Wu
    iScience.2024; 27(2): 108783.     CrossRef
  • The role of hepatokines in NAFLD
    Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, Hans-Ulrich Häring, Morris F. White
    Cell Metabolism.2023; 35(2): 236.     CrossRef
  • The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease
    Li Qin, Junru Wu, Xuejing Sun, Xuewei Huang, Wei Huang, Chunyan Weng, Jingjing Cai
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise
    Ji Ye Lim, Eunju Kim
    Metabolites.2023; 13(9): 979.     CrossRef
  • Hepatokine Profile in Adolescents with Polycystic Ovary Syndrome: A Case–Control Study
    Aikaterini Giannouli, Charikleia Stefanaki, Christos Kouskoutis, Marianna Konidari, Iliana Mani, Konstantina Konidari, Sophia L. Markantonis, Aimilia Mantzou, Spyridon P. Dourakis, Efthymios Deligeoroglou, Flora Bacopoulou
    Journal of Clinical Medicine.2023; 12(17): 5744.     CrossRef
  • The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
    Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Djuro Macut, Dušan Mladenović
    Current Issues in Molecular Biology.2023; 45(11): 9084.     CrossRef
  • Sulforaphane decreases serum selenoprotein P levels through enhancement of lysosomal degradation independent of Nrf2
    Xinying Ye, Takashi Toyama, Keiko Taguchi, Kotoko Arisawa, Takayuki Kaneko, Ryouhei Tsutsumi, Masayuki Yamamoto, Yoshiro Saito
    Communications Biology.2023;[Epub]     CrossRef
  • “Alphabet” Selenoproteins: Implications in Pathology
    Carmen Beatrice Dogaru, Carmen Duță, Corina Muscurel, Irina Stoian
    International Journal of Molecular Sciences.2023; 24(20): 15344.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and the heart
    Stan Driessen, Sven M. Francque, Stefan D. Anker, Manuel Castro Cabezas, Diederick E. Grobbee, Maarten E. Tushuizen, Adriaan G. Holleboom
    Hepatology.2023;[Epub]     CrossRef
  • Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis
    Ruirui Yu, Zhoutian Wang, Miaomiao Ma, Ping Xu, Longjian Liu, Alexey A. Tinkov, Xin Gen Lei, Ji-Chang Zhou
    Antioxidants.2022; 11(7): 1263.     CrossRef
  • Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
    Meenakshi Vachher, Savita Bansal, Bhupender Kumar, Sandeep Yadav, Taruna Arora, Nalini Moza Wali, Archana Burman
    Journal of Cellular Biochemistry.2022; 123(10): 1553.     CrossRef
  • Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
    Bing Yang, Liqing Lu, Dongmei Zhou, Wei Fan, Lucía Barbier-Torres, Justin Steggerda, Heping Yang, Xi Yang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Cytokines and regulation of glucose and lipid metabolism in the obesity
    V. I. Scherbakov, G. A. Skosyreva, T. I. Ryabichenko, O. O. Obukhova
    Obesity and metabolism.2022; 19(3): 317.     CrossRef
  • SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway
    Yi Chen, Xinjue He, Xueyang Chen, Youming Li, Yini Ke
    Journal of Cellular Physiology.2021; 236(5): 3800.     CrossRef
  • Hepatokines and metabolism: Deciphering communication from the liver
    Sharon O. Jensen-Cody, Matthew J. Potthoff
    Molecular Metabolism.2021; 44: 101138.     CrossRef
  • Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
    Sechang Oh, Takehiko Tsujimoto, Bokun Kim, Fumihiko Uchida, Hideo Suzuki, Seiichiro Iizumi, Tomonori Isobe, Takeji Sakae, Kiyoji Tanaka, Junichi Shoda
    JHEP Reports.2021; 3(3): 100253.     CrossRef
  • Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
    Chance S. Friesen, Chelsea Hosey-Cojocari, Sherwin S. Chan, Iván L. Csanaky, Jonathan B. Wagner, Brooke R. Sweeney, Alec Friesen, Jason D. Fraser, Valentina Shakhnovich
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Association of Urinary and Dietary Selenium and of Serum Selenium Species with Serum Alanine Aminotransferase in a Healthy Italian Population
    Teresa Urbano, Tommaso Filippini, Daniela Lasagni, Tiziana De Luca, Peter Grill, Sabrina Sucato, Elisa Polledri, Guy Djeukeu Noumbi, Marcella Malavolti, Annalisa Santachiara, Thelma A. Pertinhez, Roberto Baricchi, Silvia Fustinoni, Bernhard Michalke, Marc
    Antioxidants.2021; 10(10): 1516.     CrossRef
  • Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease
    Kaitlin Day, Lucia A. Seale, Ross M. Graham, Barbara R. Cardoso
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
    Tae Hyun Kim, Dong-Gyun Hong, Yoon Mee Yang
    Biomedicines.2021; 9(12): 1903.     CrossRef
  • Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis
    Jarosław Jerzy Sak, Andrzej Prystupa, Paweł Kiciński, Dorota Luchowska-Kocot, Ewa Kurys-Denis, Hanna Bis-Wencel
    World Journal of Hepatology.2021; 13(12): 2071.     CrossRef
  • Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men
    Scott A Willis, Jack A Sargeant, Thomas Yates, Toshinari Takamura, Hiroaki Takayama, Vinay Gupta, Emily Brittain, Joe Crawford, Siôn A Parry, Alice E Thackray, Veronica Varela-Mato, David J Stensel, Rachel M Woods, Carl J Hulston, Guruprasad P Aithal, Jam
    The Journal of Nutrition.2020; 150(5): 1076.     CrossRef
  • Targeting fibrinogen‐like protein 1 is a novel therapeutic strategy to combat obesity
    Hung‐Tsung Wu, Szu‐Chi Chen, Kang‐Chih Fan, Chun‐Heng Kuo, Shin‐Yu Lin, Shu‐Huei Wang, Chih‐Jen Chang, Hung‐Yuan Li
    The FASEB Journal.2020; 34(2): 2958.     CrossRef
  • Nonalcoholic fatty liver disease and cardiovascular disease phenotypes
    Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina
    SAGE Open Medicine.2020; 8: 205031212093380.     CrossRef
  • Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis
    Anna Baran, Julia Nowowiejska, Julita Anna Krahel, Tomasz W. Kaminski, Magdalena Maciaszek, Iwona Flisiak
    International Journal of Molecular Sciences.2020; 21(13): 4594.     CrossRef
  • The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
    Adrian M. Gonzalez-Gil, Leticia Elizondo-Montemayor
    Nutrients.2020; 12(6): 1899.     CrossRef
  • Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More
    Ryouhei Tsutsumi, Yoshiro Saito
    Biological and Pharmaceutical Bulletin.2020; 43(3): 366.     CrossRef
  • Selenium and selenoprotein P in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, Antonis Goulas, Leonidas Duntas
    Hormones.2020; 19(1): 61.     CrossRef
  • The Effects of Endoplasmic-Reticulum-Resident Selenoproteins in a Nonalcoholic Fatty Liver Disease Pig Model Induced by a High-Fat Diet
    Pengzu Wang, Zhuang Lu, Meng He, Baoming Shi, Xingen Lei, Anshan Shan
    Nutrients.2020; 12(3): 692.     CrossRef
  • The risk of pregnancy‐associated hypertension in women with nonalcoholic fatty liver disease
    Young Mi Jung, Seung Mi Lee, Subeen Hong, Ja Nam Koo, Ig Hwan Oh, Byoung Jae Kim, Sun Min Kim, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Sue Shin, Errol R. Norwitz, Chan‐Wook Park, Jong Kwan Jun, Won Kim, Joong Shin Park
    Liver International.2020; 40(10): 2417.     CrossRef
  • Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
    Janinah Baclaocos, John James Mackrill
    Current Nutraceuticals.2020; 1(1): 42.     CrossRef
  • Selenium and Selenoproteins in Adipose Tissue Physiology and Obesity
    Alexey A. Tinkov, Olga P. Ajsuvakova, Tommaso Filippini, Ji-Chang Zhou, Xin Gen Lei, Eugenia R. Gatiatulina, Bernhard Michalke, Margarita G. Skalnaya, Marco Vinceti, Michael Aschner, Anatoly V. Skalny
    Biomolecules.2020; 10(4): 658.     CrossRef
  • Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines
    Justine Faramia, Giada Ostinelli, Virginie Drolet-Labelle, Frédéric Picard, André Tchernof
    Current Opinion in Pharmacology.2020; 52: 67.     CrossRef
  • Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
    David Carneros, Guillermo López-Lluch, Matilde Bustos
    Nutrients.2020; 12(11): 3472.     CrossRef
  • Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
    Gian Paolo Caviglia, Chiara Rosso, Angelo Armandi, Melania Gaggini, Fabrizia Carli, Maria Lorena Abate, Antonella Olivero, Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Amalia Gastaldelli, Elisabetta Bugianesi
    International Journal of Molecular Sciences.2020; 21(22): 8838.     CrossRef
  • Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?
    Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Natalia Wasilewska, Eugeniusz Tarasow, Malgorzata Wojtkowska, Dariusz Marek Lebensztejn
    Advances in Medical Sciences.2019; 64(2): 280.     CrossRef
  • Dietary pattern associated with selenoprotein P and MRI-derived body fat volumes, liver signal intensity, and metabolic disorders
    Romina di Giuseppe, Sandra Plachta-Danielzik, Manja Koch, Ute Nöthlings, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans-Peter Müller, Jan Kassubek, Gunnar Jacobs, Wolfgang Lieb
    European Journal of Nutrition.2019; 58(3): 1067.     CrossRef
  • Cytokines and Abnormal Glucose and Lipid Metabolism
    Jie Shi, Jiangao Fan, Qing Su, Zhen Yang
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Role of exercise-induced hepatokines in metabolic disorders
    Gaël Ennequin, Pascal Sirvent, Martin Whitham
    American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E11.     CrossRef
  • Metabolomics signature associated with circulating serum selenoprotein P levels
    Romina di Giuseppe, Manja Koch, Ute Nöthlings, Gabi Kastenmüller, Anna Artati, Jerzy Adamski, Gunnar Jacobs, Wolfgang Lieb
    Endocrine.2019; 64(3): 486.     CrossRef
  • Secretomics to Discover Regulators in Diseases
    Parkyong Song, Yonghoon Kwon, Jae-Yeol Joo, Do-Geun Kim, Jong Hyuk Yoon
    International Journal of Molecular Sciences.2019; 20(16): 3893.     CrossRef
  • Impact of Lipotoxicity on Tissue “Cross Talk” and Metabolic Regulation
    Magdalene K. Montgomery, William De Nardo, Matthew J. Watt
    Physiology.2019; 34(2): 134.     CrossRef
  • The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
    Matthew J Watt, Paula M Miotto, William De Nardo, Magdalene K Montgomery
    Endocrine Reviews.2019; 40(5): 1367.     CrossRef
  • Inter-organ cross-talk in metabolic syndrome
    Christina Priest, Peter Tontonoz
    Nature Metabolism.2019; 1(12): 1177.     CrossRef
  • Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
    Swe Mar Oo, Hirofumi Misu, Yoshiro Saito, Mutsumi Tanaka, Seiji Kato, Yuki Kita, Hiroaki Takayama, Yumie Takeshita, Takehiro Kanamori, Toru Nagano, Masatoshi Nakagen, Takeshi Urabe, Naoto Matsuyama, Shuichi Kaneko, Toshinari Takamura
    Scientific Reports.2018;[Epub]     CrossRef
  • NAFLD and cardiovascular disease
    Elisabete Martins, Ana Oliveira
    Porto Biomedical Journal.2018; 3(2): e2.     CrossRef
  • The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men
    Jack A. Sargeant, Guruprasad P. Aithal, Toshinari Takamura, Hirofumi Misu, Hiroaki Takayama, Jessica A. Douglas, Mark C. Turner, David J. Stensel, Myra A. Nimmo, David R. Webb, Thomas Yates, James A. King
    Applied Physiology, Nutrition, and Metabolism.2018; 43(5): 482.     CrossRef
  • Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study
    Teruki Miyake, Sakiko Yoshida, Shin Yamamoto, Shinya Furukawa, Osamu Yoshida, Sayaka Kanzaki, Hidenori Senba, Toru Ishihara, Mitsuhito Koizumi, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Internal Medicine.2018; 57(19): 2799.     CrossRef
  • Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation
    Ibrahim Cetindağlı, Muammer Kara, Alpaslan Tanoglu, Veysel Ozalper, Serkan Aribal, Yusuf Hancerli, Mehmet Unal, Onur Ozarı, Serdar Hira, Mustafa Kaplan, Yusuf Yazgan
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(5): 516.     CrossRef
  • Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels
    Teruki Miyake, Masashi Hirooka, Osamu Yoshida, Shinya Furukawa, Teru Kumagi, Mitsuhito Koizumi, Shin Yamamoto, Taira Kuroda, Eiji Arimitsu, Eiji Takeshita, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Journal of Gastroenterology.2017; 52(2): 237.     CrossRef
  • Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
    Ruth C. R. Meex, Matthew J. Watt
    Nature Reviews Endocrinology.2017; 13(9): 509.     CrossRef
  • Circulating selenoprotein P levels in relation to MRI‐derived body fat volumes, liver fat content, and metabolic disorders
    Romina di Giuseppe, Manja Koch, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans‐Peter Müller, Jan Kassubek, Gunnar Jacobs, Ute Nöthlings, Wolfgang Lieb
    Obesity.2017; 25(6): 1128.     CrossRef
  • Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes
    Natsumi Tajima-Shirasaki, Kiyo-aki Ishii, Hiroaki Takayama, Takayoshi Shirasaki, Hisakazu Iwama, Keita Chikamoto, Yoshiro Saito, Yasumasa Iwasaki, Atsushi Teraguchi, Fei Lan, Akihiro Kikuchi, Yumie Takeshita, Koji Murao, Seiichi Matsugo, Shuichi Kaneko, H
    Journal of Biological Chemistry.2017; 292(26): 10791.     CrossRef
  • Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
    Miaoxin Chen, Bo Liu, David Wilkinson, Amy T. Hutchison, Campbell H. Thompson, Gary A. Wittert, Leonie K. Heilbronn
    Obesity Research & Clinical Practice.2017; 11(2): 227.     CrossRef
  • Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
    Hak Soo Kim, Yong Kyun Cho
    The Korean Journal of Gastroenterology.2017; 69(6): 333.     CrossRef
  • Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
    Yong-ho Lee, Sang-Guk Lee, Chan Joo Lee, Soo Hyun Kim, Young-Mi Song, Mi Ra Yoon, Byung Hun Jeon, Jae Hyuk Lee, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Scientific Reports.2016;[Epub]     CrossRef
  • Implication of hepatokines in metabolic disorders and cardiovascular diseases
    Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi
    BBA Clinical.2016; 5: 108.     CrossRef
  • Selenoproteins: Antioxidant selenoenzymes and beyond
    Holger Steinbrenner, Bodo Speckmann, Lars-Oliver Klotz
    Archives of Biochemistry and Biophysics.2016; 595: 113.     CrossRef
  • Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines
    Kyoung-Jin Oh, Da Lee, Won Kim, Baek Han, Sang Lee, Kwang-Hee Bae
    International Journal of Molecular Sciences.2016; 18(1): 8.     CrossRef
  • Pathogenesis of nonalcoholic steatohepatitis
    Wensheng Liu, Robert D. Baker, Tavleen Bhatia, Lixin Zhu, Susan S. Baker
    Cellular and Molecular Life Sciences.2016; 73(10): 1969.     CrossRef
  • Stéatose et résistance à l’insuline : implication des hépatokines
    C. Bertrand, P. Valet, I. Castan-Laurell
    Obésité.2016; 11(3): 170.     CrossRef
  • Pathophysiology of Non Alcoholic Fatty Liver Disease
    Salvatore Petta, Amalia Gastaldelli, Eleni Rebelos, Elisabetta Bugianesi, Piergiorgio Messa, Luca Miele, Gianluca Svegliati-Baroni, Luca Valenti, Ferruccio Bonino
    International Journal of Molecular Sciences.2016; 17(12): 2082.     CrossRef
  • Alterations in serum levels of fetuin A and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: A case-control study
    Sahar A. Ali, Walaa M.H. Nassif, Dalia H.A. Abdelaziz
    Clinics and Research in Hepatology and Gastroenterology.2016; 40(4): 465.     CrossRef
  • Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
    Sven M. Francque, Denise van der Graaff, Wilhelmus J. Kwanten
    Journal of Hepatology.2016; 65(2): 425.     CrossRef
  • “Omics” of Selenium Biology: A Prospective Study of Plasma Proteome Network Before and After Selenized-Yeast Supplementation in Healthy Men
    Indu Sinha, Kubra Karagoz, Rachel L. Fogle, Christopher S. Hollenbeak, Arnold H. Zea, Kazim Y. Arga, Anne E. Stanley, Wayne C. Hawkes, Raghu Sinha
    OMICS: A Journal of Integrative Biology.2016; 20(4): 202.     CrossRef
  • Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation
    Sandra Carias, Ana Lia Castellanos, Valery Vilchez, Rashmi Nair, Anna Christina Dela Cruz, Jennifer Watkins, Terrence Barrett, Patel Trushar, Karyn Esser, Roberto Gedaly
    Journal of Gastroenterology and Hepatology.2016; 31(3): 628.     CrossRef
  • Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes
    Sofiya Gancheva, Alessandra Bierwagen, Kirti Kaul, Christian Herder, Peter Nowotny, Sabine Kahl, Guido Giani, Birgit Klueppelholz, Birgit Knebel, Paul Begovatz, Klaus Strassburger, Hadi Al-Hasani, Jesper Lundbom, Julia Szendroedi, Michael Roden
    Diabetes.2016; 65(7): 1849.     CrossRef
  • Selenoprotein P is not elevated in gestational diabetes mellitus
    Alev E. Altinova, Ozlem T. Iyidir, Cigdem Ozkan, Damla Ors, Merve Ozturk, Ozlem Gulbahar, Nuray Bozkurt, Fusun B. Toruner, Mujde Akturk, Nuri Cakir, Metin Arslan
    Gynecological Endocrinology.2015; 31(11): 874.     CrossRef
  • Selenium and Human Health: Witnessing a Copernican Revolution?
    Ewa Jablonska, Marco Vinceti
    Journal of Environmental Science and Health, Part C.2015; 33(3): 328.     CrossRef
  • Toenail selenium and risk of type 2 diabetes: the ORDET cohort study
    Marco Vinceti, Sara Grioni, Dorothea Alber, Dario Consonni, Carlotta Malagoli, Claudia Agnoli, Marcella Malavolti, Valeria Pala, Vittorio Krogh, Sabina Sieri
    Journal of Trace Elements in Medicine and Biology.2015; 29: 145.     CrossRef
  • Expression of Selenoprotein Genes Is Affected by Obesity of Pigs Fed a High-Fat Diet
    Hua Zhao, Ke Li, Jia-Yong Tang, Ji-Chang Zhou, Kang-Ning Wang, Xin-Jie Xia, Xin Gen Lei
    The Journal of Nutrition.2015; 145(7): 1394.     CrossRef
  • Hepatokines as a Link between Obesity and Cardiovascular Diseases
    Hye Jin Yoo, Kyung Mook Choi
    Diabetes & Metabolism Journal.2015; 39(1): 10.     CrossRef
  • The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
    Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu
    International Journal of Molecular Sciences.2015; 16(12): 29207.     CrossRef
  • Dietary selenate attenuates adiposity and improves insulin sensitivity in high-fat diet-induced obese mice
    Choon Young Kim, Yuyan Zhu, Kimberly K. Buhman, Kee-Hong Kim
    Journal of Functional Foods.2015; 17: 33.     CrossRef
  • Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gyuri Kim, Yong-ho Lee, Young Min Park, Jungghi Kim, Heesuk Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Dae Jung Kim
    Medicine.2015; 94(27): e1103.     CrossRef
  • Inhibition of SH2-domain-containing inositol 5-phosphatase (SHIP2) ameliorates palmitate induced-apoptosis through regulating Akt/FOXO1 pathway and ROS production in HepG2 cells
    Sattar Gorgani-Firuzjaee, Khosrow Adeli, Reza Meshkani
    Biochemical and Biophysical Research Communications.2015; 464(2): 441.     CrossRef
  • Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK
    Jinmi Lee, Seok-Woo Hong, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(2): 177.     CrossRef
  • AMPK activator-mediated inhibition of endoplasmic reticulum stress ameliorates carrageenan-induced insulin resistance through the suppression of selenoprotein P in HepG2 hepatocytes
    Tae Woo Jung, So Young Lee, Ho Cheol Hong, Hae Yoon Choi, Hye Jin Yoo, Sei Hyun Baik, Kyung Mook Choi
    Molecular and Cellular Endocrinology.2014; 382(1): 66.     CrossRef
  • HIF‐1α Expression as a Protective Strategy of HepG2 Cells Against Fatty Acid‐Induced Toxicity
    Wonbaek Yoo, Kyung Hee Noh, Jae Hee Ahn, Ji Hee Yu, Ji A. Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Tae Woo Kim, Hyo Joon Kim, Nan Hee Kim
    Journal of Cellular Biochemistry.2014; 115(6): 1147.     CrossRef
  • Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics
    Jacklyn N. Hellwege, Nicholette D. Palmer, Julie T. Ziegler, Carl D. Langefeld, Carlos Lorenzo, Jill M. Norris, Toshinari Takamura, Donald W. Bowden
    Gene.2014; 534(1): 33.     CrossRef
  • Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children
    B-J Ko, S M Kim, K H Park, H S Park, C S Mantzoros
    International Journal of Obesity.2014; 38(12): 1497.     CrossRef
  • The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels
    Kyung-Soo Kim, Hyun-Ju Oh, Dae-Jung Kim, Soo-Kyung Kim, Seok Won Park, Yong-Wook Cho, Kap-Bum Huh
    Endocrine Journal.2013; 60(12): 1295.     CrossRef
Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
Diabetes Metab J. 2012;36(2):128-135.   Published online April 17, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.2.128
  • 3,968 View
  • 31 Download
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

Aldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system. We investigated the renoprotective effect of the selective aldosterone receptor blocker eplerenone, the angiotensin converting enzyme inhibitor lisinopril, and combined eplerenone and lisinopril treatment in type 2 diabetic rats.

Methods

Animals were divided into six groups as follows: Otsuka Long-Evans Tokushima Fatty (OLETF) rat control, OLETF rats treated with a low dose of eplerenone (50 mg/kg/day), OLETF rats treated with a high dose of eplerenone (200 mg/kg/day), OLETF rats treated with lisinopril (10 mg/kg/day), OLETF rats treated with a combination of both drugs (eplerenone 200 mg/kg/day and lisinopril 10 mg/kg/day), and obese non-diabetic Long-Evans Tokushima Otsuka rats for 26 weeks.

Results

Urinary albumin excretion was significantly lower in the lisinopril group, but not in the eplerenone group. Urinary albumin excretion was decreased in the combination group than in the lisinopril group. Glomerulosclerosis and renal expression of type I and type IV collagen, plasminogen activator inhibitor-1, transforming growth factor-β1, connective tissue growth factor, and fibronectin mRNA were markedly decreased in the lisinopril, eplerenone, and combination groups.

Conclusion

Eplerenone and lisinopril combination showed additional benefits on type 2 diabetic nephropathy compared to monotherapy of each drug.

Citations

Citations to this article as recorded by  
  • Up-Date on Diabetic Nephropathy
    Maria Chiara Pelle, Michele Provenzano, Marco Busutti, Clara Valentina Porcu, Isabella Zaffina, Lucia Stanga, Franco Arturi
    Life.2022; 12(8): 1202.     CrossRef
  • The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
    A. Yu. Zharikov, S. O. Filinova, O. N. Mazko, O. G. Makarova, I. P. Bobrov, V. M. Bryukhanov
    Bulletin of Siberian Medicine.2021; 20(2): 29.     CrossRef
  • Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
    Johannes J. Kovarik, Christopher C. Kaltenecker, Oliver Domenig, Marlies Antlanger, Marko Poglitsch, Chantal Kopecky, Marcus D. Säemann
    Diabetes Therapy.2021; 12(9): 2485.     CrossRef
  • Diabetic nephropathy: An update on pathogenesis and drug development
    Vikram Rao A/L B Vasanth Rao, Sean Hong Tan, Mayuren Candasamy, Subrat Kumar Bhattamisra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 754.     CrossRef
  • Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
    Li‐Jing Sun, Yan‐Ni Sun, Jian‐Ping Shan, Geng‐Ru Jiang
    Journal of Diabetes Investigation.2017; 8(4): 609.     CrossRef
  • New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?
    Anna Gromotowicz-Poplawska, Piotr Szoka, Patrycjusz Kolodziejczyk, Karol Kramkowski, Marzena Wojewodzka-Zelezniakowicz, Ewa Chabielska
    Experimental Biology and Medicine.2016; 241(17): 1888.     CrossRef
  • Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell
    Jing Xiao, Weijun Chen, Yijun Lu, Xiaoli Zhang, Chensheng Fu, Zhenwen Yan, Zhenxing Zhang, Zhibin Ye
    Inflammation Research.2015; 64(8): 603.     CrossRef
  • Eplerenone reduces arterial thrombosis in diabetic rats
    Agnieszka Zakrzeska, Anna Gromotowicz-Popławska, Janusz Szemraj, Piotr Szoka, Wioleta Kisiel, Tomasz Purta, Irena Kasacka, Ewa Chabielska
    Journal of the Renin-Angiotensin-Aldosterone System.2015; 16(4): 1085.     CrossRef
  • Pharmacological modulation of fibrinolytic response – In vivo and in vitro studies
    Karol Kramkowski, Agnieszka Leszczynska, Wlodzimierz Buczko
    Pharmacological Reports.2015; 67(4): 695.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal